Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.53 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | KIF11 | P52732 | 1/20 | 0.45 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.44 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | EDNRB | P24530 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1133335 | 0.98 | CRHBP (0.51) | CRHBPCRHR2ESR1ESR2KIF11 | |
| SCHEMBL32684616 | 0.83 | CRHBP (0.56) | CRHBPCRHR2ESR1ESR2KIF11 | |
| SCHEMBL9875296 | 0.83 | CRHBP (0.60) | CRHBPCRHR2ESR1ESR2KIF11 | |
| Glycine SCHEMBL28258751 | 0.83 | CRHBP (0.49) | CRHBPCRHR2ESR1ESR2KIF11 | |
| SCHEMBL16053132 | 0.82 | GABBR2 (0.43) | GABBR2GABBR1CYP2D6CYP1A2PKM | |
| SCHEMBL11588080 | 0.82 | GABBR2 (0.43) | GABBR2GABBR1CYP2D6CYP1A2PKM | |
| Hydrochloric Acid SCHEMBL27517458 | 0.82 | CRHBP (0.48) | CRHBPCRHR2ESR1ESR2KIF11 | |
| SCHEMBL27546315 | 0.82 | CRHBP (0.48) | CRHBPCRHR2ESR1ESR2KIF11 | |
| SCHEMBL7019908 | 0.82 | CRHBP (0.58) | CRHBPCRHR2ESR1ESR2KIF11 | |
| SCHEMBL7019902 | 0.82 | CRHBP (0.54) | CRHBPCRHR2ESR1ESR2KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4492707-A | ANTILIPEMIC AGENT | FARMITALIA CARLO ERBA S.P.A. (IT) | 1985-01-08 | — | — | US | claimed |
| US-20110230665-A1 | SYNTHESIS OF RENIN INHIBITORS INVOLVING A CYCLOADDITION REACTION | MICKEL STUART JOHN | 2011-09-22 | — | — | US | disclosed |
| US-7973175-B2 | pyrrolidine chemical intermediates useful in the synthesis of drugs, especially enzyme inhibitors, such as Aliskiren | NOVARTIS AG (CH) | 2011-07-05 | — | — | US | disclosed |
| EP-2287153-A1 | Synthesis Of Renin Inhibitors Involving A Cycloaddition Reaction | Novartis AG (CH) | 2011-02-23 | — | — | EP | disclosed |
| EP-1931629-B1 | SYNTHESIS OF RENIN INHIBITORS INVOLVING A CYCLOADDITION REACTION | NOVARTIS AG (CH) | 2010-12-22 | — | — | EP | disclosed |
| US-20080255369-A1 | Synthesis of Renin Inhibitors Involving a Cycloaddition Reaction | NOVARTIS AG (CH) | 2008-10-16 | — | — | US | disclosed |
| EP-1931629-A1 | SYTHESIS OF RENIN INHIBITORS INVOLVING A CYCLOADDITION REACTION | Novartis AG (CH) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007039183-A1 | SYTHESIS OF RENIN INHIBITORS INVOLVING A CYCLOADDITION REACTION | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| CN-1223636-A | Matrix metalloproteinase inhibitors | PHARMACIA & UPJOHN SPA (IT) | 1999-07-21 | — | — | CN | disclosed |
| US-4595532-A | N-(substituted-methyl)-azetidin-2-ones | UNIVERSITY OF NOTRE DAME DU LAC (US) | 1986-06-17 | — | — | US | disclosed |
| US-4588738-A | N-imidazolyl derivatives of 1,2,3,4-tetrahydro-naphthalene and indan as platelet aggregation inhibitors | FARMITALIA CARLO ERBA S.P.A. (IT) | 1986-05-13 | — | — | US | disclosed |
| US-4492707-A | ANTILIPEMIC AGENT | FARMITALIA CARLO ERBA S.P.A. (IT) | 1985-01-08 | — | — | US | disclosed |
| EP-0116432-A2 | Improvements in or relating to N-(substituted-methyl)-azetidin-2-ones | THE UNIVERSITY OF NOTRE DAME DU LAC (US) | 1984-08-22 | — | — | EP | disclosed |
| US-4097670-A | ANTIBIOTICS | E. R. SQUIBB & SONS, INC. (US) | 1978-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255369-A1 | Synthesis of Renin Inhibitors Involving a Cycloaddition Reaction | REN, AGTR1, AGTR2 | CRHBP 1632/4885CRHR2 95/4885ESR1 2965/4885 |
| US-20110230665-A1 | SYNTHESIS OF RENIN INHIBITORS INVOLVING A CYCLOADDITION REACTION | REN, AGTR1, AGTR2 | CRHBP 1632/4885CRHR2 95/4885ESR1 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.